NeoGenomics to Report Q1 2026 Earnings on April 28

The clinical laboratory company will announce its first quarter financial results next month.

Apr. 7, 2026 at 12:42pm

Got story updates? Submit your updates here. ›

A close-up view of intricate banking machinery and financial infrastructure, rendered in a high-contrast, industrial style to conceptually represent the complex inner workings of the cancer diagnostics industry.NeoGenomics' upcoming earnings report will shed light on the company's role in the complex machinery of cancer diagnostics and the financial health of the oncology testing industry.Fort Myers Today

NeoGenomics, a leading provider of cancer-focused genetic testing and information services, announced that it will report its financial results for the first quarter of 2026 on Tuesday, April 28, 2026. The company, headquartered in Fort Myers, Florida, will host a conference call and webcast to discuss the quarterly results on the same day.

Why it matters

As a major player in the rapidly evolving field of cancer diagnostics, NeoGenomics' quarterly earnings reports provide important insights into the company's performance and the broader trends impacting the oncology testing market. Investors and industry analysts closely follow NeoGenomics' financial results to gauge the company's growth trajectory and competitive positioning.

The details

NeoGenomics will release its Q1 2026 financial results after the market close on April 28, 2026. The company will host a conference call and live webcast to discuss the results at 8:30 a.m. Eastern Time the same day. A replay of the webcast will be available on the company's website following the call.

  • NeoGenomics will report Q1 2026 financial results on April 28, 2026.
  • The company will host a conference call and webcast to discuss the results on April 28, 2026 at 8:30 a.m. Eastern Time.

The players

NeoGenomics

A leading provider of cancer-focused genetic testing and information services, headquartered in Fort Myers, Florida.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be closely watching NeoGenomics' Q1 2026 earnings report for signs of the company's continued growth and performance in the oncology testing market.

The takeaway

NeoGenomics' upcoming earnings announcement will provide valuable insights into the state of the cancer diagnostics industry and the company's ability to capitalize on emerging trends and technologies in this rapidly evolving field.